Comprehensive assessment of the safety of olodaterol 5 mu g in the Respimat (R) device for maintenance treatment of COPD: comparison with the long-acting beta(2)-agonist formoterol

Koch, Andrea; Watz, Henrik; Maleki-Yazdi, M. Reza; Bothner, Ulrich; Tetzlaff, Kay; Voss, Florian und McGarvey, Lorcan (2017): Comprehensive assessment of the safety of olodaterol 5 mu g in the Respimat (R) device for maintenance treatment of COPD: comparison with the long-acting beta(2)-agonist formoterol. In: Npj Primary Care Respiratory Medicine, Bd. 27, 60

Abstract

This analysis provides a comprehensive clinical assessment of the long-term safety of the licensed dose of olodaterol (5 mu g once daily [QD] via Respimat (R) inhaler) in patients with chronic obstructive pulmonary disease by exploring the occurrence of acknowledged side effects of long-acting beta(2)-agonists as well as those included in the olodaterol and formoterol labels. We analysed pooled data from two replicate, double-blind studies of olodaterol (5 mu g QD via Respimat (R)) compared to formoterol (12 mu g twice daily [BID]) or placebo over 48 weeks (1222.13, NCT00793624;1222.14, NCT00796653). Patients could continue their background treatment. The analysis considered adverse events (AEs) typically associated with beta(2)-agonists, including cardiovascular events, as well as administration-related events. Descriptive statistics were provided for the incidence of AEs and aggregated AEs. The analysis included 1379 patients: 460 placebo, 459 olodaterol and 460 formoterol;AEs were reported by 70.9, 71.7 and 69.1% of patients, respectively. Exposure-adjusted incidence rates of cardiac AEs (arrhythmia and myocardial ischaemia) and cough were numerically lower in the olodaterol group than the formoterol group, while nasopharyngitis, throat irritation, metabolism and psychiatric disorders were numerically higher in the olodaterol group. The most frequent event in the olodaterol group was nasopharyngitis (placebo 8.0%;olodaterol 12.9%;formoterol 10.0%). Except for cough (incidence rate ratio of 0.46 [95% confidence interval 0.24, 0.89] in favour of olodaterol), there were no significant differences between active groups. In conclusion, olodaterol 5 mu g QD was well tolerated over 48 weeks with a typical beta(2)-agonist safety profile comparable to formoterol 12 mu g BID.

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 2055-1010
• Sprache: Englisch